APAC Life Science Instrumentation Market

APAC Life Science Instrumentation Market Size (2024 to 2029)

The size of the life science instrumentation market in the APAC region is expected to grow at a CAGR of 6.01% from 2024 to 2029 and be worth USD 17.44 billion by 2029 from USD 13.03 billion in 2024.

Increased spending on research and development, growing public and private financing for life science research, rising demand for analytical instruments, and rising incidence of target diseases and genetic disorders are propelling the expansion of the Asia Pacific market. In addition, the market is advancing due to the increasing adoption of applications such as capillary electrophoresis with mass spectroscopy, flow cytometry techniques, and others.

Furthermore, one of the major factors driving the growth of the life science instrumentation market in Asia-Pacific is the rising frequency of hospital-acquired infections and quick advancements in NGS platforms. In addition, the pharmaceutical industry's increasing investment in drug discovery and development is anticipated to increase the demand for life science tools for drug validation. In the next few years, the APAC life science instrumentation market will benefit from the severity of chronic diseases and the demand for early detection and treatment.

Additionally, as people become more aware of the importance of early detection and treatment of chronic diseases, there will be greater demand for life science instruments. The demand for life science instrumentation technology in the pharmaceutical and biotechnology industries is fueled by rising public health awareness and proactive government policies to reduce chronic disease-related mortality. The market is further expected to be driven by the rising R&D spending, growing food safety concerns, technological developments in analytical instruments, and the availability of financing for life science research.

On the other hand, unawareness about instruments, insufficient research infrastructure, a scarcity of skilled professionals, and technical limitations associated with qPCR and dPCR techniques, as well as the high cost of advanced microscopes, are projected to pose a negative effect on the growth of the life science instrumentation market in Asia-Pacific. Some of the instruments are incredibly advanced and complex, necessitating the development of novel data computation and information extraction paradigms. These instruments also have regular standardization processes and maintenance procedures, both of which require qualified employees. Furthermore, the high cost of life science and chemical instrumentation restricts the market's expansion.

This research report on the APAC life science instrumentation market has been segmented and sub-segmented into the following categories.

By Technology:

• PCR
• Spectroscopy
• Microscopy
• Chromatography
• Electrophoresis
• Next-generation sequencing (NGS)
• Flow Cytometry
• Centrifuges
• Others

By Application:

• Clinical and Diagnostic
• Research
• Others

By End-user:

• Hospitals and diagnostic laboratories
• Pharmaceutical and biotechnology companies
• Academic & Research institutions
• Others

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

The Asia Pacific region is a significant revenue generator in the global life science instrumentation market. Strategic expansions by the key market participants in emerging Asian nations, the growing pharmaceutical market in India and China, and conferences, displays, and symposia on analytical instruments are promoting this regional market growth. Due to increased research activities in countries such as India, the market in the Asia Pacific is expected to grow at a high CAGR during the forecast period. In addition, increasing public-private investments in life science research and technological advancements in analytical equipment are driving the market for life science instruments and chemicals. Heart and brain disorders, such as Alzheimer's disease, constitute a significant threat to society. This increase in burden is attributable to population growth, rapid aging, and a shift in emerging countries from poverty-related diseases to lifestyle diseases. Furthermore, expanding healthcare facilities in emerging economies such as China, India, and other nations create a considerable demand for life science instruments, contributing to the market's growth.

KEY MARKET PLAYERS:

Danaher, Thermo Fisher Scientific, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Illumina, Inc., PerkinElmer, Inc., BD, Bruker, and Hitachi High-Technologies Corporation are some of the notable companies in the life science instrumentation market in the APAC region and profiled in this report.